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701Abstracts
drug; bladder training or pelvic ﬂoor exercises; a pessary;
second line treatment; or estrogens. Costs related to
urinary incontinence were determined over the ﬁrst,
second and third year after diagnosis. RESULTS: We
identiﬁed 2663 women with newly diagnosed urinary
incontinence, yielding an overall incidence of 13 cases 
per 1000 person-years. For 53% of the newly identiﬁed
urinary incontinent women, the type of incontinence was
not included in the diagnosis. Overall, 86% of the newly
identiﬁed urinary incontinent women were treated within
one year after diagnosis; in 60% use of an absorbent
product was the ﬁrst treatment, 10% started on a bladder
relaxant drug and 10% was initially advised bladder
training or pelvic ﬂoor exercises. The type of treatment
mostly did not change over time. The mean direct costs
for treatment over the ﬁrst year amounted to €392 per
woman. Most of the costs were due to the use of
absorbent products, a cost that remained stable in subse-
quent treatment years. CONCLUSION: Our ﬁnding that
the type of urinary incontinence was only classiﬁed in 
a minority of the newly identiﬁed urinary incontinent
women and only a small part of the women was initially
advised bladder training or pelvic ﬂoor exercises, ques-
tions the usefulness of the guidelines for treatment of
urinary incontinence.
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OBJECTIVES: To compare the use of intravenous (IV)
versus subcutaneous (SC) Eprex maintenance therapy in
the chronic kidney disease (CKD) population in Canada.
METHODS: Retrospective chart review of patients with
CKD. Patients included if: 1) receiving Eprex for anemia
associated with CKD for at least 6 months; 2) were stable
on current renal replacement modality (i.e., predialysis,
peritoneal dialysis, hemodialysis) for at least 6 months.
Patients were excluded if treated for less than 2 months
via the current route of administration. Patients were ran-
domly selected from patient lists generated from each of
the sites. If a patient did not fulﬁll inclusion and exclu-
sion criteria, the immediate next patient was evaluated
for inclusion. This analysis focused on all hemodialysis
patients treated with IV (n = 28) or SC (n = 166). Dif-
ference in dose was analyzed by analysis of covariance
controlling for age, sex, presence of diabetes, use of ACE
Inhibitors, history of cancer, and route of administra-
tion. RESULTS: Mean dose (± standard deviation) for
patients treated with SC Eprex was 159IU/kg/week 
(±124IU/kg/week) as compared to a mean dose of 
124IU/kg/week in IV patients (±112IU/kg/week). Neither
the unadjusted difference (p = 0.160), nor the difference
adjusted for the pre-deﬁned covariates (p = 0.852) were
signiﬁcantly different between the two routes of adminis-
tration. The cost of Eprex for SC treatment ($147/week
± $103) versus IV therapy ($133/week ± $110) was not
signiﬁcantly different (p = 0.496). No difference was
detected in hemoglobin levels between SC (115.4g/L) 
and IV (113.6g/L) patients (p = 0.515). These results are
limited by the small sample of patients in the IV group as
well as by the fact that all IV patients were found in 
a single hemodialysis unit. This analysis indicates that
further research may be necessary to optimize the dosing
of biologic agents such as Eprex. CONCLUSIONS: Route
may not play a signiﬁcant role in the Eprex dose required
for treating anemia in CKD patients.
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OBJECTIVES: To assess the efﬁciency of two surgical
procedures for the treatment of female Stress Urinary
Incontinence (SUI): Tension-Free Vaginal Tape (TVT) 
and Open Burch Colposuspension (OBC), through an
economic evaluation. METHODS: A cost-minimization
model was undertaken as evidence from randomized 
controlled clinical trials show there are no statistically 
signiﬁcant differences between efﬁcacy rates of both pro-
cedures in the short and medium term. The model was
carried out from the public payer’s perspective (National
Health System) with a time horizon of 3 months. The
resource use and costs with each procedure were com-
pared in terms of pre-surgical resources, the surgical inter-
vention itself, hospitalization, post-surgical follow-up and
management of complications. Outcomes of the model
were the average cost per patient and the incremental cost
(additional cost or savings) between the two procedures.
Resource use data was collected from a panel of 7 clini-
cal opinion leaders specialized in female SUI (3 urologists
and 4 gynaecologists). All unit costs were retrieved from
published sources and refer to 2002 Euros. Sensitivity
analyses were performed for key parameters of the model.
RESULTS: In the base case, the overall average cost 
per patient was €1680.56 and €3015.86 with the TVT
and OBC respectively. Incremental cost per patient was
